Edition:
United States

Consun Pharmaceutical Group Ltd (1681.HK)

1681.HK on Hong Kong Stock

6.72HKD
21 Sep 2017
Change (% chg)

HK$-0.03 (-0.44%)
Prev Close
HK$6.75
Open
HK$6.70
Day's High
HK$6.72
Day's Low
HK$6.70
Volume
130,000
Avg. Vol
851,320
52-wk High
HK$6.88
52-wk Low
HK$3.70

Latest Key Developments (Source: Significant Developments)

Consun Pharmaceutical Group posts ‍HY profit attributable RMB184.8 million
Thursday, 24 Aug 2017 12:04am EDT 

Aug 24 (Reuters) - Consun Pharmaceutical Group Ltd <1681.HK>:Board declared payment of an interim dividend of HKD0.096 per share for six months ended 30 june 2017..‍HY profit attributable RMB184.8 million an increase of 27.1%​.Board has declared payment of an interim dividend of HKD0.096 per share.Revenue for HY amounted to RMB769.4 million, up 70.3%.  Full Article

Consun Pharmaceutical Group signs commitment letter with Bnp Paribas
Friday, 17 Mar 2017 04:40am EDT 

Consun Pharmaceutical Group Ltd <1681.HK> : Company signed a commitment letter with Bnp Paribas .Lender conditionally to grant company a three year term loan facility of up to hk$560 million.  Full Article

Consun Pharmaceutical Group says entered into share buy-back agreement with First Kind
Monday, 6 Feb 2017 05:12pm EST 

Consun Pharmaceutical Group Ltd <1681.HK>: Entered into share buy-back agreement with First Kind . Agreed to acquire and First Kind agreed to dispose of 146.1 million shares at total consideration of HK$560.7 million .Proposes payment of a special dividend of HK$0.1 per share.  Full Article

Consun pharmaceutical group- HY profit attributable RMB145.4 mln up approximately 20 pct<1681.HK>
Tuesday, 30 Aug 2016 12:10am EDT 

Consun Pharmaceutical Group Ltd <1681.HK>: Pharmaceutical group- HY revenue amounted to RMB 451.9 million representing an increase of approximately 16.7% . HY profit attributable amounted to RMB145.4 million representing an increase of approximately 20.0% . Says the board has declared the payment of an interim dividend of RMB0.045 per share .  Full Article

Consun Pharmaceutical announces further acquisition of about 5.42% equity interest in Guangxi Yulin Pharmaceutical<1681.HK>
Tuesday, 16 Aug 2016 10:13am EDT 

Consun Pharmaceutical Group Ltd <1681.HK>: Connected transaction - further acquisition of approximately 5.42% equity interest in Guangxi Yulin Pharmaceutical Group Co., Ltd. <1681.HK> . Unit has entered into the equity transfer agreements with the seventh round vendors on 15 August 2016 and 16 August 2016 . Says consideration to be funded by internal resources of the group . Deal for consideration of approximately RMB47.3 million .  Full Article

Consun Pharmaceutical says unit entered equity transfer agreements<1681.HK>
Thursday, 11 Aug 2016 08:58am EDT 

Consun Pharmaceutical Group Ltd <1681.HK>: Voluntary announcement-further acquisition of approximately 10.69% equity interest in guangxi yulin pharmaceutical group co., ltd. <1681.HK> . Subsidiary (a wholly-owned subsidiary of the company) has entered into the equity transfer agreements with the sixth round vendors . Deal for consideration of approximately RMB93.2 million . Equity transfer agreements with the sixth round vendors during the period from 20 July 2016 to 8 August 2016 . "Sixth Round Vendors" a total of 146 individuals, all of whom are citizens of the PRC . "Subsidiary" (Guangzhou Consun Pharmaceutical Company Limited.), a wholly-owned subsidiary of the Company established in the PRC .  Full Article

BRIEF-Consun Pharmaceutical Group posts ‍HY profit attributable RMB184.8 million

* Board declared payment of an interim dividend of HKD0.096 per share for six months ended 30 june 2017.